Holen Sie sich die Stockscreener-App
0.7701
6.09%
-0.0499
Handel nachbörslich:
.77
-0.000100
-0.01%
Schlusskurs vom Vortag:
$0.82
Offen:
$0.73
24-Stunden-Volumen:
354.42K
Relative Volume:
0.37
Marktkapitalisierung:
$3.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.52M
KGV:
-0.0414
EPS:
-18.58
Netto-Cashflow:
$-16.61M
1W Leistung:
-8.21%
1M Leistung:
-6.43%
6M Leistung:
-92.67%
1J Leistung:
-97.31%
1-Tages-Spanne:
$0.73
$0.7984
1-Wochen-Bereich:
$0.702
$0.98
52-Wochen-Spanne:
$0.702
$56.00
Revelation Biosciences Inc Stock (REVB) Company Profile
Firmenname
Revelation Biosciences Inc
Sektor
Branche
Telefon
650-800-3717
Adresse
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie REVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.7701 | 3.87M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Revelation Biosciences Inc Aktie (REVB) Neueste Nachrichten
Phase 2b Trial Data on Treatment for Inflammation Due Soon - streetwisereports.com
Equities Analysts Offer Predictions for REVB FY2028 Earnings - Defense World
Revelation Biosciences Raises $4M in Public Offering - TipRanks
REVBRevelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering - mx.advfn.com
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - mx.advfn.com
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - mx.advfn.com
Revelation Biosciences Inc (REVB) Shares Rise Despite Market Challenges - News Heater
REVB stock touches 52-week low at $0.86 amid sharp annual decline By Investing.com - Investing.com South Africa
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering - Insider Monkey
Revelation Biosciences sets terms for $4 million public offering By Investing.com - Investing.com Canada
Revelation Biosciences, Inc. Announces Closing Of $4 Million Public Offering - marketscreener.com
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering - Business Wire
REVB stock touches 52-week low at $0.86 amid sharp annual decline - Investing.com Canada
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering - BioSpace
Revelation Biosciences Announces Pricing Of $4 Million Public Offering - marketscreener.com
Revelation Biosciences sets terms for $4 million public offering - Investing.com Australia
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Revelation Biosciences announces pricing of $4M public offering - MSN
Revelation Biosciences Board Member Resigns Amid New Role - TipRanks
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Revelation Biosciences board member steps down amid new focus - Investing.com Australia
Revelation Biosciences board member steps down amid new focus By Investing.com - Investing.com Canada
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors - The Joplin Globe
REVB: New Market Potential and Quarterly Results - Research Tree
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 - BioSpace
Revelation Biosciences (REVB) Projected to Post Earnings on Friday - Defense World
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients - BioSpace
REVB: New Target Market Announced - Research Tree
Peripheral Blood Mononuclear Cells Market Size to Hit USD 774.41 Bn by 2034 - Precedence Research
Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Insider Monkey
Pre-market Movers: IBO, ALUR, GCTK, TELA... - RTTNews
Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics - GlobeNewswire
REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com
REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks
Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire
What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World
REVB: 2025 Is the Year for Measurable Progress - Research Tree
Revelation Biosciences Inc. (REVB) reports earnings - Quartz
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ
Finanzdaten der Revelation Biosciences Inc-Aktie (REVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):